Stilbene Derivative Cyclophilin Inhibitor Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases related to cyclophilin, such as viral infections and inflammatory responses, lack effective inhibitors with improved pharmaceutical profiles.
Innovation Solution
Development of a stilbene derivative that binds to the active pocket of cyclophilin, inhibiting its function and potentially treating cyclophilin-related diseases by preventing or reducing symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cyclophilin inhibitors are developed to treat diseases, then therapeutic efficacy is improved, but pharmaceutical profile (solubility, stability, toxicity) deteriorates
Solution Approach 1:
The patent introduces specific substituent groups (R1-R6) at different positions of the stilbene core structure to optimize local interactions with cyclophilin binding sites while controlling solubility and stability properties. Different substituents are strategically placed to achieve selective binding affinity without compromising pharmaceutical profile.
Solution Approach 2:
The invention combines the stilbene core structure with various functional groups (hydroxyl, methoxyl, halogen, alkyl groups) to create composite molecular structures that simultaneously achieve high binding affinity to cyclophilin and improved pharmaceutical properties including solubility and metabolic stability.
2Reliability
If high binding affinity to cyclophilin is achieved, then inhibitory activity is improved, but selectivity and reduced off-target effects worsen
Solution Approach 1:
The patent employs specific substituent patterns at defined positions on the stilbene structure to create localized interaction zones that match the geometry and chemical properties of the cyclophilin binding pocket, thereby achieving high selectivity and affinity while minimizing interactions with off-target proteins.
Solution Approach 2:
Instead of starting with a known cyclophilin ligand and modifying it, the patent uses a stilbene core structure (different from traditional immunophilin ligands) and optimizes it for cyclophilin binding, thereby achieving novel binding modes that may improve selectivity and reduce cross-reactivity with other proteins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stilbene derivative effectively inhibits cyclophilin function, demonstrating potential as a therapeutic agent for various diseases, including viral infections, cardiovascular diseases, and inflammatory conditions, with improved pharmaceutical properties.
Implementation Method 1
Cyclosporine, one of available cyclophilin inhibitors, binds in the hydrophobic pocket of CyP A to thus inhibit PPIase activity. The stilbene derivative effectively inhibits cyclophilin function
Data Source
AI summary
This invention relates to a stilbene derivative and a method of preparing the same, and more particularly to a novel stilbene derivative for inhibiting the function of cyclophilin, which is effective at the prevention of cyclophilin-related diseases or at the treatment of symptoms of such diseases, and to a method of preparing the same.